Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesProteasome inhibitors in the treatment of multiple myeloma
Leukemia, 09/15/09
Shah JJ et al. – In this spotlight review, the authors provide an overview of the current state of the art use of bortezomib and other proteasome inhibitors against multiple myeloma, and highlight areas for future study that will further optimize the ability to benefit patients with this disease.
Related Articles
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer
Cancer Immunology, Immunotherapy, 10/26/09
Relevance Score: 92%
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells
Oncogene, 11/05/09
Relevance Score: 89%
Proteasomes in Human Bronchoalveolar Lavage Fluid After Burn and Inhalation Injury
Journal of Burn Care & Research, 10/21/09
Relevance Score: 89%
The sperm proteasome during sperm capacitation and fertilization
Journal of Reproductive Immunology, 10/14/09
Relevance Score: 89%
Nrf2 cysteine residues are critical for oxidant/electrophile-sensing, keap1-dependent ubiquitination-proteasomal degradation, and transcription activation
Molecular Pharmacology, 10/12/09
Relevance Score: 88%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Pulmonary Alveolar Proteinosis as a Terminal Complication in a Case of Myelodysplastic Syndrome with idic(20q-)
Acta Haematologica, 12/04/09
Environmental-mediated drug resistance: a target for multiple myeloma therapy
Expert Review of Hematology, 12/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of patients with advanced bladder cancer following major response to systemic chemotherapy
Expert Review of Anticancer Therapy, 12/04/09
ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer
Expert Review of Anticancer Therapy, 12/04/09
Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer
Expert Review of Anticancer Therapy, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor